Abstract In this study, we evaluated the effect of boron (B) as boric acid (BA) on body weight (b.w.); blood glucose; plasma insulin; lipase and paraoxonase (PON1) activities; and serum triglyceride, total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, lipid peroxidation (MDA), and total antioxidant capacity (TAC) in streptozotocin (STZ)-induced experimental diabetes in rats. Sixty Wistar albino rats (200-250 g) were divided into six groups of ten. The groups received the following treatment: group 1, control group; group 2, 50 mg/kg (b.w.) i.p. STZinduced diabetes; group 3, 5 mg/kg (b.w.) B; group 4, 10 mg/kg (b.w.) B; group 5, diabetes + 5 mg/kg (b.w.) B; and group 6, diabetes + 10 mg/kg (b.w.) B. The experiment lasted 4 weeks. Increased serum MDA levels with diabetes were significantly reduced and although it is not statistically significant, serum TAC levels approached to values of control group; also, insignificant increases were observed in HDL cholesterol levels in experimental diabetic rats with treatment 5 and 10 mg/kg B. Furthermore, body weight, plasma insulin, and lipase activities increased insignificantly, blood glucose and serum LDL cholesterol decreased significantly, and total cholesterol levels decreased insignificantly in the diabetes + 10 mg/kg B group. There was no difference between the groups in terms of plasma PON1 activities and serum triglyceride levels. In conclusion, B may have beneficial effects on some biochemical parameters changes in experimental diabetes, and in order to determine the full effect of this element on the metabolism, further studies are required which use various dosages and compounds of B.
Introduction
Diabetes mellitus (DM) is a metabolic disease characterized by high or low levels of fasting blood glucose, due to the partial or complete absence of insulin hormone and due to the equality of carbohydrate, lipid, and protein metabolism damage [1] [2] [3] . Oxidative stress can be caused by increased free radicals, result from suppression of the antioxidant system, or both of these effects, or occur due to a decreased antioxidant defense capacity [4, 5] . Hyperglycemia is reported to cause an increase in free radicals as a result of glucose autooxidation, which in turn leads to an increase in lipid peroxidation and oxidative stress that has been reported to destroy the antioxidant defense system [4, [6] [7] [8] [9] . It is stated that diabetes and complications associated with the disease increase free radical production due to non-enzymatic glycation, metabolic stress due to changes in energy metabolism, sorbitol pathway activity, hypoxia, and tissue damage resulting from ischemia-reperfusion and, furthermore, alter the antioxidant defense system [10] . Synthetic drugs have multiple side effects in the treatment of diabetes mellitus. Hence, the discovery and investigation of alternative hypoglycemic agents are of considerable importance. Various vitamins, minerals, and plants are used for this purpose.
The mechanism of action of the biochemical effects of boron (B), which is thought to be essential for humans and animals, has not yet been fully explained. Although the biochemical mediating functions of B on bone and mineral metabolism [11] [12] [13] , endocrine function [13] [14] [15] [16] , energy metabolism [17] [18] [19] [20] [21] , and oxidative stress [17] [18] [19] [20] [21] [22] [23] [24] [25] have been revealed, knowledge about the effect of B on diabetes is limited [18, 26, 27] . The current study was intended to contribute further studies in this area. Accordingly, rats were treated with streptozotocin (STZ), to induce experimental diabetes, and the effects of B (5 and 10 mg/kg) on live weight, blood glucose, plasma insulin, lipase and paraoxonase (PON1) activities, serum lipid profile, malondialdehyde (MDA) as indicator of lipid peroxidation, and total antioxidant capacity (TAC) were investigated.
Material and Methods

Chemicals
Boron as boric acid (BA) is purchased from Carlo Erba (Cat. No. 302177) and STZ is acquired from Sigma-Aldrich (Cat. No. S0130). All other reagents were purchased from commercial sources.
Animals, Diets, and Experimental Design
The study was approved by the Committee of Local Ethics Committee of Erciyes University Animal Experiments (ERÜ HADYEK) (Decision No. 12/22 of 11.01.2012). Sixty male Wistar albino rats weighing 200-250 g were divided into six groups of ten in each group. The rats were housed in polycarbonate cages (3-4 rats per cage), in coarse sawmills, under the conditions of conventional laboratory animal housekeeping conditions (controlled temperature (21 ± 2°C), humidity (50 ± 5%), air change (cycle), light (12 h light, 12 h dark)). The groups received the following treatment: group 1, control group; group 2, 50 mg/kg (b.w.) i.p. STZ-induced diabetes; group 3, 5 mg/kg (b.w.) B; group 4, 10 mg/kg (b.w.) B; group 5, diabetes + 5 mg/kg (b.w.) B; and group 6 diabetes + 10 mg/kg (b.w.) B. Boric acid was given to the animals via gavage. The animals were fed with commercial pelleted feed that would meet the daily nutrient requirement. Animals were given water and feed, ad libitum throughout the experiment.
Doses of B used in the study are based on the result of Price et al. [28] study. These investigators found no adverse effects in B up to 10 mg/kg (b.w.) in rats, negative effects observed at doses of 10 mg, and no adverse effects (NOAEL) found in 10 mg B/kg (b.w.)/day, compared to blood B levels. Low levels (LOAEL) at which symptoms of toxicity could develop were 13 mg B/kg (b.w.)/day. Streptozotocin (50 mg/kg (b.w.)/day) was dissolved in 0.1 ml citrate buffer (pH 4.5) and given single dose intraperitoneally (i.p.) to rats. Streptozotocin forms diabetes by destroying beta cells of the pancreas within 3 days of administration [29] . For this reason, 3 days after STZ administration, fasting blood glucose levels were started to be monitored with a glucometer. Animals with fasting blood glucose levels of up to 200 mg/dl [6, 9] and with polyuria, polyphagia, and polydipsia were considered diabetic. In the study, five animals did not develop diabetes (in 5 and 10 mg/kg B-treated diabetic groups) and two animals (in 5 and 10 mg/kg B-treated groups) died because of the wrong gavage practice.
Body weights and blood glucose levels of rats were weekly recorded during experimental period. The experiment lasted 4 weeks.
Blood Collection and Biochemical Analyzes
At the end of the experiment, animals were fasted for 12 h and then, anesthesia was induced pentobarbital (40 mg/kg body weight), which did not affect the levels of the parameters to be analyzed. Blood was taken from the hearts by using the puncture method and collected in tubes with non-anticoagulated for serum and in tubes with Li-heparin for plasma. Blood were centrifuged at 1300×g for 10 min at 4°C and then, serum and plasma were separated.
Plasma insulin (Spi Bio, France, cat. no. A05105), lipase (Spinreact, Spain, cat. no. 1001275) activities, and MDA (Cayman, USA, cat no. 10009055) levels were determined with ELISA (Bio-Tek, ELx50, USA); serum PON1 (Rel Assay, Turkey, cat no. 0031) activity, triglyceride, total cholesterol, high-density lipoprotein (HDL) cholesterol, lowdensity lipoprotein (LDL) cholesterol (Spinreact, Spain, cat nos. 41031, 41021, 1001098, 41023, respectively), and TAC (Rel Assay, Turkey, cat no. 0017) levels were determined with spectrophotometer (Shimadzu UV Model 1208) by using commercial kits. Serum B levels were measured by the ICP/ MS (Agilent 7500a series) instrument.
Statistical Analysis
Statistical analysis of the data was done with the SPSS 20.0 package program for Microsoft. The difference between the groups was determined by one-way analysis of variance (ANOVA). When the F-score was significant, Duncan's multiple range test was used to determine which group originated the difference. The data are given as the standard error of the mean and the mean.
Results
Body Weight and Blood Glucose Levels
At the end of the experiment, no statistically significant difference was determined between the control group and the 5 and 10 mg/kg (b.w.) B-treated groups. Body weight decreased (P < 0.05, 0.01, 0.001) in all diabetic groups compared to the control and only B-treated groups. However, on the last week of the experiment, there was a numerical increase in the body weights of the 10 mg B-administered diabetic rats (Table 1) .
There was no statistically significant difference in blood glucose levels between the control and 5 and 10 mg/kg Btreated groups. It was determined that blood glucose levels in diabetic rats were significantly higher than those in control and only B-administered groups. Blood glucose levels of diabetic animals with the administration of 10 mg/kg B significantly decreased from the week 3 (Table 2 ; P < 0.001).
Plasma Insulin, PON1 Levels, and Lipase Activity
Although there was no statistically significant effect on insulin and lipase activities, the addition of B to diabetic groups resulted in a numerical increase, especially at 10 mg/kg B. There was no difference between groups in terms of plasma PON1 levels (Table 3) .
Serum MDA, TAC, Lipid, and B Levels
Compared to the control group, serum MDA levels were significantly lower in the only 5 and 10 mg/kg B-treated groups. The lowest MDA level was found in the 10 mg/kg B-treated group. Increased MDA levels in the diabetic group were significantly reduced by 5 and 10 mg/kg B administration (P < 0.001; Table 4 ). On the other hand, there was no statistically significant difference between the groups in terms of serum TAC levels (P > 0.05), but it was found that the levels decreased numerically only in diabetic rats. Although statistical significance was not significant, treatment of 5 and 10 mg/kg B showed that TAC levels were closer to the control group values (Table 4) .
Total cholesterol levels in the diabetic group showed a significant increase (P < 0.01) compared to those in the control groups. No difference was determined in serum total cholesterol levels between the control and only 5 and 10 mg/kg Btreated groups (P > 0.05). The addition of B to diabetic groups caused a statistically insignificant decrease in total cholesterol levels ( Table 4) . The highest serum HDL cholesterol level was determined in the control group. The HDL cholesterol levels were significantly lower in the diabetic group and both the 5 and 10 mg/ kg B groups than the control group (P < 0.001). However, a statistically insignificant increase in HDL cholesterol levels was observed in 5 and 10 mg/kg B-administered diabetic rats (Table 4) .
There was no difference between only B-treated groups and control groups in terms of serum LDL cholesterol levels, and also, no statistically significant difference was found between control group and diabetic group. However, compared to the diabetic group, a significant reduction in LDL cholesterol levels was observed in the only 5 and 10 mg/kg B-treated groups and diabetes + 10 mg/kg B group (P < 0.01; Table 4 ).
Serum B levels in the diabetic group were significantly lower than those in the only B-treated groups and control groups (P < 0.001). The highest level of B was found in the 10 mg/kg B-treated group. The addition of 5 mg/kg B to diabetic group did not change serum B level; adding 10 mg/ kg B resulted in a significant increase in B level (Table 4) .
Discussion
Diabetes is a metabolic disorder characterized by a high incidence of fasting blood glucose due to partial or complete loss of insulin hormone. Diabetes is accompanied by a reduction in the organ's greatest energy and tissue reserves [1] [2] [3] , along with glycogenolysis, lipolysis, and glyconeogenesis and as well as their biochemical activities, and oxidative degradation -not significant; *P < 0.05; **P < 0.01; ***P < 0.001 of amino acids resulting in muscle loss and loss of tissue proteins. Changes in body weight, biochemical parameters, and oxidative stress markers in experimental diabetic rats have been reported in several studies [6-8, 18, 29-35] . However, only a limited number of studies [18, 26, 27] have investigated the effect of B on body weight and biochemical changes in rats with diabetes.
Body Weight, Blood Glucose, and Plasma Insulin
Balasubashini et al. [6] stated that the increase in blood glucose and insulin secretion in female diabetic Wistar rats (40 mg/kg STZ) was possibly due to the oxidative stress induced in the pancreas as a result of the deterioration of DNA structure by STZ. Zafar and Naqvi [31] also reported increased plasma glucose levels and decreased live weight loss with polydipsia, in STZ (45 mg/kg)-induced diabetic albino rats, and these effects were attributed to the deleterious effects of STZ, which caused DNA alkylation and generated necrotic lesions and hyperglycemia. These investigators suggested that the direct alkalizing effect of STZ may be caused by hypoglycemia, hypersensitivity, and cellular necrosis resulting from the destruction of the pancreatic β-cells, which may lead to a decrease in live weight in diabetic animals. In another study [8] , it was reported that decreased plasma insulin level in Wistar rats with STZ (35 mg/kg) diabetes was due to cytotoxic damage of STZ on pancreatic β-cells with increased plasma glucose on day 2. Also, in the another study [8] , live weight b eg an to de cr ea s e f r o m w e ek 5 , a s a r es u l t of gluconeoenegenesis and lipolysis in diabetic Wistar rats (45 mg/kg STZ). Demir and Yilmaz [5] have reported that the predominantly diminished live weight occurs as a result of increased catabolic reactions in structural proteins, due to decreased insulin levels. In male Wistar rats, body weight decreased and blood/ plasma glucose levels were increased by treatment with 50 mg/kg [18, 35] STZ for 1 month and 55 mg/kg [33] STZ for 6 weeks. However, decreased live weight (within 7-10 days) [2, 7, 29, 32] and serum insulin levels [29, 34] , in addition to increased glucose levels (within 2-4 days) [7, 29, 34] , were reported in rats with experimental diabetes by treatment with 60 mg/kg STZ.
Oliveira et al. [2] suggested that changes in glucose homeostasis in the presence of diabetes may be a consequence of low-glucose uptake by peripheral tissues, such as increased hepatic glycogenolysis and glyconeogenesis. Cheng et al. [7] also reported that the loss of body weight in diabetic rats may be related to the loss of tissue proteins due to hyperglycemic conditions and increased muscle loss and also to the loss of β-cells in the Langerhans islets with STZ injection. In another study [9] , STZ (65 mg/kg)-induced diabetic male Wistar rats showed significant weight loss due to insufficiency of cells to -not significant; ***P < 0.001 produce energy from glucose and due to a loss of live weight with dehydration caused by polyuria. Furthermore, in the same study, the authors emphasized that energy production was accompanied by an initial activation of gluconeogenesis, followed by excessive mobilization of muscle proteins and fats.
In accordance with the findings of the above researchers [2, 5-8, 18, 29-33, 35] , in this study, in all diabetic groups, the increase in blood glucose levels and the decrease in plasma insulin levels and live weight may be due to a decrease or lack of insulin release. Thus, an increase in blood glucose and gluconeogenesis, and a decrease in tissue lipids and proteins, consequently increased muscle loss, which was associated with the destruction of the pancreatic Langerhans islets β-cells, by STZ.
Although it has been suggested that B may be complexed with the hydroxyl group present in the glucose structure and that blood glucose levels may be suppressed [36, 37] , no statistically significant difference was found between the control and 5 and 10 mg/kg B-treated groups in terms of blood glucose levels in the study presented. Hence, this suggests that other influencing factors exist, for example, the B dose administered to the rats, the form, the delivery schedule, the concentration of B taken naturally with the food content, differences in the dietary values of the rations or the individual differences in the animals, and their race and gender. In addition, it was observed that the administration of B to diabetic groups did not affect body weight and plasma insulin levels, but there was a numerical increase in these parameters in the diabetes + 10 mg/kg B group compared to other groups with diabetes. However, blood glucose levels in experimental diabetic rats were significantly higher than those in the control and the B only-treated group. From the third week, blood glucose levels in the diabetes + 10 mg/kg B group were significantly lower than those in the other diabetic groups, but still significantly higher than those in the control group. These results suggest that 10 mg/kg B may have a hypoglycemic effect, affecting energy metabolism in the presence of stress in rats.
Plasma Lipase
Lipase hydrolyzes triglycerides to monoglycerides; plasma lipase activity is increased in cases of pancreatitis [38] . Several studies have investigated the effects of STZ-induced diabetes on pancreatic lipase activity, in rats treated with various STZ doses [39] [40] [41] [42] [43] [44] . The histopathological examination of pancreatic tissue has not been done in the present study. However, it has been shown that the increase in plasma lipase activities in diabetic rats, because of STZ, which is used to generate experimental diabetes, may damage pancreatic Langerhans islets β-cells [43] and cause changes in pancreatic exocrine secretion [44] . However, no significant effect of B administration on the increased plasma lipase activities with diabetes was found.
Serum and Plasma Oxidative Stress Parameters
Oxidative stress, caused by persistent hyperglycaemia, disrupts the antioxidant defense system and produces reactive oxygen species as a result of glucose autooxidation [8, 9] . Oxidative stress can be caused by increased free radicals and/or as a result of suppression of the antioxidant system or reduction of the antioxidant defense capacity [4, 5] . It is stated that hyperglycemia causes the increase of free radicals, and this may result in an increase in lipid peroxidation [6] .
The present study suggests that elevated serum MDA levels in diabetic rats, without affecting serum TAC levels, may be due to lipid peroxidation [8, 45, 46] resulting in free radical formation without any effect on the antioxidant capacity during hyperglycemia [45, 46] . In this study, compared to only diabetic group, 5 and 10 mg/kg B administration to diabetic groups reduced the serum MDA levels significantly and increased numerically serum TAC levels, suggesting that B may lead to antioxidant activity by reducing lipid peroxidation. Plasma PON1 levels are significantly reduced in diabetic groups [30, 45, [47] [48] [49] [50] of different race rats in which experimental diabetes is formed using various doses of STZ. In the present study, although the statistical significance is not important, it can be argued that the diabetic groups may be associated with oxidative stress and hyperglycaemia due to inhibition of this enzyme activity, as a result of a decrease in plasma PON1 levels, glycemia due to diabetes, or increased lipid peroxidation products [50] . However, the addition of B to the diabetic groups did not affect PON1 values.
Serum Lipid Parameters
Diabetes mellitus is a metabolic disorder associated with lipid abnormalities. It is known that an increase in plasma free fatty acids plays an important role in the development of type 2 diabetes, which is caused by insulin resistance [51] . Thus, lipids play an important role in the development of diabetes. Morever, an increase in plasma lipids is a risk factor for coronary heart disease [51] [52] [53] .
In the present study, it was possible that the differences in serum triglyceride, total cholesterol, and LDL cholesterol levels between the control group and only the B-added groups, as well as the significantly lower HDL cholesterol levels in the B-treated groups than the control, resulted from the test period (4 weeks). In this study, serum triglyceride and total cholesterol levels were significantly increased, LDL cholesterol levels were not significantly increased, and HDL cholesterol levels were significantly decreased, in all groups with diabetes. The application of B does not cause a positive effect on the increasing levels, particularly, according to the diabetic group; an insignificant decrease in triglyceride and total cholesterol levels and a significant decrease in LDL levels were determined in the diabetes + 10 mg/kg B group. In addition, there was a statistically insignificant increase in HDL cholesterol values of the 5 and 10 mg/kg B-administered diabetic rats. These results suggest that B is more effective in the presence of a stress factor. It is also possible that higher doses may have a stronger antihyperlipidemic efficacy in rats. This effect of B may be due to the change in lipolysis level in the insulin control and/or the activities of enzymes involved in cholesterol synthesis [7, 54] .
Serum B
In addition to being an important component of body tissue, minerals have many physiological functions, including roles in metabolism and energy production, among others. The trace elements influence glucose metabolism by acting as cofactors for the activation of the insulin-receptor site, increasing insulin sensitivity by insulin synthesis, release, and storage [55, 56] . In general, the excretion of some minerals, such as chromium, zinc [55, [57] [58] [59] [60] , manganese [58] [59] [60] , and magnesium [55, [57] [58] [59] [60] , is higher in individuals with diabetes mellitus than in healthy individuals, due to polyuria caused by hyperglycemia [59] ; therefore, the plasma levels of these minerals are lower in diabetic patients [55, [58] [59] [60] .
In the present study, serum B levels of the diabetic group decreased due to changes in mineral balance as a result of damage to pancreatic function [61] and possibly attributed to an increase in B excretion due to polyuria caused by hyperglycemia. There was no difference in serum B level between the diabetes group and diabetes + 5 mg/kg B group. However, there was a significant increase in serum B level with the addition of 10 mg/kg B. It suggests that administration of 10 mg/kg B may have a positive effect on mineral balance.
Conclusion
Elemental B may have useful effects on some biochemical parameter alterations induced by diabetes. In order to define the full effect of this element on the metabolism, without creating any adverse effects, further studies investigating several dosages and compounds of B are needed.
